Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Neurobiol Dis ; 120: 12-20, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30149182

RESUMO

The lateral hypothalamus contains neurons producing orexins that promote wakefulness and suppress REM sleep as well as neurons producing melanin-concentrating hormone (MCH) that likely promote REM sleep. Narcolepsy with cataplexy is caused by selective loss of the orexin neurons, and the MCH neurons appear unaffected. As the orexin and MCH systems exert opposing effects on REM sleep, we hypothesized that imbalance in this REM sleep-regulating system due to activity in the MCH neurons may contribute to the striking REM sleep dysfunction characteristic of narcolepsy. To test this hypothesis, we chemogenetically activated the MCH neurons and pharmacologically blocked MCH signaling in a murine model of narcolepsy and studied the effects on sleep-wake behavior and cataplexy. To chemoactivate MCH neurons, we injected an adeno-associated viral vector containing the hM3Dq stimulatory DREADD into the lateral hypothalamus of orexin null mice that also express Cre recombinase in the MCH neurons (MCH-Cre::OX-KO mice) and into control MCH-Cre mice with normal orexin expression. In both lines of mice, activation of MCH neurons by clozapine-N-oxide (CNO) increased rapid eye movement (REM) sleep without altering other states. In mice lacking orexins, activation of the MCH neurons also increased abnormal intrusions of REM sleep manifest as cataplexy and short latency transitions into REM sleep (SLREM). Conversely, a MCH receptor 1 antagonist, SNAP 94847, almost completely eliminated SLREM and cataplexy in OX-KO mice. These findings affirm that MCH neurons promote REM sleep under normal circumstances, and their activity in mice lacking orexins likely triggers abnormal intrusions of REM sleep into non-REM sleep and wake, resulting in the SLREM and cataplexy characteristic of narcolepsy.


Assuntos
Hormônios Hipotalâmicos/metabolismo , Melaninas/metabolismo , Narcolepsia/metabolismo , Neurônios/fisiologia , Hormônios Hipofisários/metabolismo , Sono REM/fisiologia , Animais , Feminino , Hormônios Hipotalâmicos/antagonistas & inibidores , Hormônios Hipotalâmicos/genética , Masculino , Melaninas/antagonistas & inibidores , Melaninas/genética , Camundongos , Camundongos Knockout , Narcolepsia/genética , Neurônios/efeitos dos fármacos , Piperidinas/farmacologia , Hormônios Hipofisários/antagonistas & inibidores , Hormônios Hipofisários/genética
2.
Toxicol Appl Pharmacol ; 319: 22-38, 2017 03 15.
Artigo em Inglês | MEDLINE | ID: mdl-28161095

RESUMO

Tributyltin chloride (TBT) is a xenobiotic used as a biocide in antifouling paints that has been demonstrated to induce endocrine-disrupting effects, such as obesity and reproductive abnormalities. An integrative metabolic control in the hypothalamus-pituitary-gonadal (HPG) axis was exerted by leptin. However, studies that have investigated the obesogenic TBT effects on the HPG axis are especially rare. We investigated whether metabolic disorders as a result of TBT are correlated with abnormal hypothalamus-pituitary-gonadal (HPG) axis function, as well as kisspeptin (Kiss) action. Female Wistar rats were administered vehicle and TBT (100ng/kg/day) for 15days via gavage. We analyzed their effects on the tin serum and ovary accumulation (as biomarker of TBT exposure), estrous cyclicity, surge LH levels, GnRH expression, Kiss action, fertility, testosterone levels, ovarian apoptosis, uterine inflammation, fibrosis, estrogen negative feedback, body weight gain, insulin, leptin, adiponectin levels, as well as the glucose tolerance (GTT) and insulin sensitivity tests (IST). TBT led to increased serum and ovary tin levels, irregular estrous cyclicity, and decreased surge LH levels, GnRH expression and Kiss responsiveness. A strong negative correlation between the serum and ovary tin levels with lower Kiss responsiveness and GnRH mRNA expression was observed in TBT rats. An increase in the testosterone levels, ovarian and uterine fibrosis, ovarian apoptosis, and uterine inflammation and a decrease in fertility and estrogen negative feedback were demonstrated in the TBT rats. We also identified an increase in the body weight gain and abnormal GTT and IST tests, which were associated with hyperinsulinemia, hyperleptinemia and hypoadiponectinemia, in the TBT rats. TBT disrupted proper functioning of the HPG axis as a result of abnormal Kiss action. The metabolic dysfunctions co-occur with the HPG axis abnormalities. Hyperleptinemia as a result of obesity induced by TBT may be associated with abnormal HPG function. A strong negative correlation between the hyperleptinemia and lower Kiss responsiveness was observed in the TBT rats. These findings provide evidence that TBT leads to toxic effects direct on the HPG axis and/or indirectly by abnormal metabolic regulation of the HPG axis.


Assuntos
Hormônios Hipotalâmicos/metabolismo , Sistema Hipotálamo-Hipofisário/metabolismo , Kisspeptinas/metabolismo , Leptina/metabolismo , Sistema Hipófise-Suprarrenal/metabolismo , Compostos de Trialquitina/toxicidade , Animais , Disruptores Endócrinos/toxicidade , Exposição Ambiental/efeitos adversos , Ciclo Estral/efeitos dos fármacos , Ciclo Estral/metabolismo , Feminino , Hormônios Hipotalâmicos/antagonistas & inibidores , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Kisspeptinas/antagonistas & inibidores , Leptina/antagonistas & inibidores , Obesidade/induzido quimicamente , Obesidade/metabolismo , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Ratos , Ratos Wistar , Reprodução/efeitos dos fármacos , Reprodução/fisiologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia
3.
Am J Physiol Endocrinol Metab ; 303(10): E1252-63, 2012 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-23011064

RESUMO

Kisspeptins (Kp), products of the Kiss1 gene, have emerged as essential elements in the control of GnRH neurons and gonadotropic secretion. However, despite considerable progress in the field, to date limited attention has been paid to elucidate the potential interactions of Kp with other neurotransmitters known to centrally regulate the gonadotropic axis. We characterize herein the impact of manipulations of key aminoacidergic (glutamate and GABA), peptidergic (NKB, Dyn, and MCH), and gaseous [nitric oxide (NO)] neurotransmission on gonadotropin responses to Kp-10 in male rats. Blockade of ionotropic glutamate receptors (of the NMDA and non-NMDA type) variably decreased LH responses to Kp-10, whereas activation of both ionotropic and metabotropic receptors, which enhanced LH and FSH release per se, failed to further increase gonadotropin responses to Kp-10. In fact, coactivation of metabotropic receptors attenuated LH and FSH responses to Kp-10. Selective activation of GABA(A) receptors decreased Kp-induced gonadotropin secretion, whereas their blockade elicited robust LH and FSH bursts and protracted responses to Kp-10 when combined with GABA(B) receptor inhibition. Blockade of Dyn signaling (at κ-opioid receptors) enhanced LH responses to Kp-10, whereas activation of Dyn and NKB signaling modestly reduced Kp-induced LH and FSH release. Finally, MCH decreased basal LH secretion and modestly reduced FSH responses to Kp-10, whereas LH responses to Kp-10 were protracted after inhibition of NO synthesis. In summary, we present herein evidence for the putative roles of glutamate, GABA, Dyn, NKB, MCH, and NO in modulating gonadotropic responses to Kp in male rats. Our pharmacological data will help to characterize the central interactions and putative hierarchy of key neuroendocrine pathways involved in the control of the gonadotropic axis.


Assuntos
Hormônio Foliculoestimulante/metabolismo , Kisspeptinas/farmacologia , Hormônio Luteinizante/metabolismo , Transmissão Sináptica/efeitos dos fármacos , Animais , Dineínas/antagonistas & inibidores , Dineínas/metabolismo , Hormônio Foliculoestimulante/sangue , Ácido Glutâmico/metabolismo , Hormônios Hipotalâmicos/agonistas , Hormônios Hipotalâmicos/antagonistas & inibidores , Hormônios Hipotalâmicos/metabolismo , Hormônio Luteinizante/sangue , Masculino , Melaninas/agonistas , Melaninas/antagonistas & inibidores , Melaninas/metabolismo , Neurocinina B/agonistas , Neurocinina B/antagonistas & inibidores , Neurocinina B/metabolismo , Óxido Nítrico/antagonistas & inibidores , Óxido Nítrico/biossíntese , Óxido Nítrico/metabolismo , Hormônios Hipofisários/agonistas , Hormônios Hipofisários/antagonistas & inibidores , Hormônios Hipofisários/metabolismo , Ratos , Ratos Wistar , Transdução de Sinais/efeitos dos fármacos , Ácido gama-Aminobutírico/metabolismo
4.
Physiol Behav ; 88(4-5): 523-8, 2006 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-16793070

RESUMO

Estradiol exerts an inhibitory effect on food intake via interactions with anorexigenic peptides, like cholecystokinin, that function to decrease meal size. It is currently unknown whether estradiol also interacts with orexigenic compounds implicated in the physiological control of food intake. Thus, the primary goal of this study was to determine whether estradiol decreases the orexigenic effect of melanin-concentrating hormone (MCH), a neuropeptide that, like estradiol, appears to influence food intake by selectively affecting the controls of meal size. Food and water intake were monitored following lateral ventricular (icv) infusions of 5 mug MCH or saline vehicle in oil- and estradiol-treated ovariectomized rats. MCH increased food intake throughout the first 4 h of the dark phase in oil-treated rats, but only for the last 2 h of the same 4-h interval in estradiol-treated rats. As a result, the orexigenic effect of MCH was significantly lower in estradiol-treated rats, relative to oil-treated rats. During this interval of MCH-stimulated feeding, a prandial increase in water intake was not observed in either oil- or estradiol-treated rats. We conclude that estradiol decreases the orexigenic effect of MCH in ovariectomized rats.


Assuntos
Ingestão de Alimentos/efeitos dos fármacos , Estradiol/farmacologia , Hormônios Hipotalâmicos/antagonistas & inibidores , Hormônios Hipotalâmicos/farmacologia , Melaninas/antagonistas & inibidores , Melaninas/farmacologia , Ovariectomia , Hormônios Hipofisários/antagonistas & inibidores , Hormônios Hipofisários/farmacologia , Animais , Escuridão , Ingestão de Líquidos/efeitos dos fármacos , Feminino , Injeções Intraventriculares , Ratos , Ratos Long-Evans
5.
Gen Comp Endocrinol ; 136(2): 270-5, 2004 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15028531

RESUMO

Melanin-concentrating hormone (MCH) evokes an increase of GEM-81 cell proliferation. This action of 10(-6)M MCH was inhibited in the presence of the following blockers: U-73122 (phospholipase C), Ro-31-8220 (PKC) or KN-93 (Ca(2+)/calmodulin-dependent kinase). The more selective PKC inhibitors, HBDDE and Go-6983, which block, respectively, PKC alpha/gamma isoform and beta1 isoform, were used. HBDDE was ineffective whereas Go-6983 reversed the proliferative response promoted by MCH. Flow cytometry assays demonstrated that MCH induces a slow and long-lasting rise in intracellular calcium, which can be blocked by U-73122. Our results also show a cAMP increase evoked by MCH. Our data support the assumption that MCH exerts its effect on GEM-81 erythrophoroma cells through activation of phosholipase C, beta1 PKC, and Ca(2+)/calmodulin-dependent PKC, and eliciting a slow, long-lasting rise in calcium, which may trigger the proliferative signal.


Assuntos
Divisão Celular/efeitos dos fármacos , Carpa Dourada , Hormônios Hipotalâmicos/farmacologia , Melaninas/farmacologia , Hormônios Hipofisários/farmacologia , Animais , Benzilaminas/farmacologia , Proteínas Quinases Dependentes de AMP Cíclico/antagonistas & inibidores , Inibidores Enzimáticos/farmacologia , Estrenos/farmacologia , Doenças dos Peixes/patologia , Hormônios Hipotalâmicos/antagonistas & inibidores , Indóis/farmacologia , Melaninas/antagonistas & inibidores , Hormônios Hipofisários/antagonistas & inibidores , Proteína Quinase C/antagonistas & inibidores , Pirrolidinonas/farmacologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/veterinária , Sulfonamidas/farmacologia , Células Tumorais Cultivadas , Fosfolipases Tipo C/antagonistas & inibidores
6.
J Neurochem ; 85(2): 338-47, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12675910

RESUMO

Leptin, the obese gene product, was reported to stimulate prolactin (PRL) secretion, but the neuroendocrine mechanism underlying this hormonal response is largely unknown. Thus, in this study we examined the involvement of several important PRL regulators in the leptin-induced PRL secretion in male rats. Compared with the values in normally fed rats, food deprivation for 3 days significantly decreased both PRL and leptin levels in the plasma. These changes were reverted to normal by a 3-day constant infusion of 75 microg/kg/day of leptin to the fasted rats, while 225 microg/kg/day of leptin further elevated both PRL and leptin levels. These four groups of animals were used for the following experiments. Results of dopamine and serotonin turnover studies in the brain and the pituitary indicated that neither of these biogenic amines plays a primary role in mediating leptin's effects on PRL. Repeated intracerebroventricular injections over 72 h of neutralizing antibodies against vasoactive intestinal peptide, PRL-releasing peptide, or beta-endorphin, did not significantly suppress the leptin actions. However, both the blockade of the melanocortin (MC) 4 receptor (R) and the immunoquenching of brain alpha-melanocyte-stimulating hormone (alpha-MSH) completely abolished the leptin-induced PRL release, and the stimulation of the MC4-R, but not the MC3-R, significantly elevated PRL levels in the fasted rats. These results suggest that alpha-MSH, a cleaved peptide from pro-opiomelanocortin of which synthesis is stimulated by leptin, may be the pivotal neuropeptide in the brain mediating the leptin's stimulatory influence on PRL secretion. It was also suggested that the MC4-R may be the primary subtype of the MC-Rs mediating this action of alpha-MSH.


Assuntos
Leptina/farmacologia , Prolactina/metabolismo , Receptores da Corticotropina/metabolismo , alfa-MSH/análogos & derivados , alfa-MSH/metabolismo , Ácido 3,4-Di-Hidroxifenilacético/metabolismo , Animais , Encéfalo/metabolismo , Dopamina/metabolismo , Relação Dose-Resposta a Droga , Jejum/fisiologia , Ácido Hidroxi-Indolacético/metabolismo , Hormônios Hipotalâmicos/antagonistas & inibidores , Soros Imunes/administração & dosagem , Injeções Intraventriculares , Leptina/sangue , Masculino , Neuropeptídeos/antagonistas & inibidores , Peptídeos Cíclicos/administração & dosagem , Hipófise/metabolismo , Prolactina/sangue , Hormônio Liberador de Prolactina , Ratos , Ratos Wistar , Receptor Tipo 3 de Melanocortina , Receptor Tipo 4 de Melanocortina , Receptores da Corticotropina/agonistas , Receptores da Corticotropina/antagonistas & inibidores , Serotonina/metabolismo , Peptídeo Intestinal Vasoativo/antagonistas & inibidores , alfa-MSH/administração & dosagem , alfa-MSH/antagonistas & inibidores , beta-Endorfina/antagonistas & inibidores , gama-MSH/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA